DNB Asset Management AS cut its stake in shares of Clorox Co (NYSE:CLX) by 11.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,625 shares of the company’s stock after selling 1,870 shares during the quarter. DNB Asset Management AS’s holdings in Clorox were worth $2,347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of the stock. Athena Capital Advisors LLC purchased a new stake in Clorox in the 4th quarter worth approximately $25,000. Meeder Asset Management Inc. purchased a new stake in Clorox in the 4th quarter worth approximately $26,000. Capital Financial Planning LLC purchased a new stake in Clorox in the 4th quarter worth approximately $32,000. City Holding Co. lifted its holdings in Clorox by 150.0% in the 4th quarter. City Holding Co. now owns 250 shares of the company’s stock worth $39,000 after buying an additional 150 shares during the period. Finally, G&S Capital LLC lifted its holdings in Clorox by 46.4% in the 4th quarter. G&S Capital LLC now owns 262 shares of the company’s stock worth $40,000 after buying an additional 83 shares during the period. Institutional investors own 76.90% of the company’s stock.
In related news, SVP Matthew T. Laszlo sold 10,585 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total transaction of $1,628,925.65. Following the completion of the transaction, the senior vice president now owns 17,994 shares of the company’s stock, valued at approximately $2,769,096.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Andrew J. Mowery sold 5,340 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $156.44, for a total value of $835,389.60. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
CLX opened at $152.34 on Wednesday. The company has a market capitalization of $19.79 billion, a PE ratio of 25.53, a PEG ratio of 3.86 and a beta of 0.32. The company has a debt-to-equity ratio of 3.08, a current ratio of 1.15 and a quick ratio of 0.66. Clorox Co has a 52 week low of $113.57 and a 52 week high of $167.70.
Clorox (NYSE:CLX) last released its earnings results on Monday, February 4th. The company reported $1.40 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.08. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.47 billion. Clorox had a return on equity of 105.97% and a net margin of 12.65%. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.77 EPS. As a group, research analysts expect that Clorox Co will post 6.31 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Wednesday, April 24th will be given a dividend of $0.96 per share. This represents a $3.84 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend is Tuesday, April 23rd. Clorox’s dividend payout ratio (DPR) is presently 61.34%.
CLX has been the subject of several research analyst reports. Zacks Investment Research upgraded Clorox from a “hold” rating to a “buy” rating and set a $177.00 price objective for the company in a report on Monday, March 11th. BMO Capital Markets set a $175.00 price objective on Clorox and gave the stock a “buy” rating in a report on Tuesday, February 5th. Wells Fargo & Co reiterated a “hold” rating and issued a $157.00 price objective on shares of Clorox in a report on Monday, February 4th. Barclays reiterated a “hold” rating and issued a $142.00 price objective on shares of Clorox in a report on Wednesday, February 6th. Finally, Citigroup set a $171.00 target price on Clorox and gave the company a “hold” rating in a research note on Tuesday, February 5th. Six equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Clorox presently has an average rating of “Hold” and a consensus target price of $151.21.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Recommended Story: Stock Split
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.